Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.

Haematologica/journal of hematology vol. 88(02):February 2003 229 ics of STI571 in a phase 1 trial in chronic myelogenous leukemia (CML) patients. Proc Am Assoc Cancer Res 2000;41:3468[abstract]. 4. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7. 5. Marin D, Marktel S, Bua M, Olavarria E, Apperley J, Goldman JM. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-α defines four different prognostic groups. Blood 2001;98:3514a[abstract]. 6. Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica 2002;87:979-88. 7. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:14416.